You can expect Protagenic Therapeutics to participate in events and presentations in which neuro-active peptides are showcased.
This is because in Spring 2016, Protagenic Therapeutics secured sufficient working capital to pursue our development goals through an expected filing of an IND application with the FDA. Our R&D team is carrying out the necessary steps to accomplish these critical tasks and to refine and enhance our science platform. We have accumulated a strong intellectual property estate and will strategically add to our IP portfolio over time. We appreciate the investor enthusiasm demonstrated with our successful financing, and we are motivated by our progress to date and for the potential of our novel lead compound to change the way mood disorders are treated.